Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | IL2 | P60568 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471881 | 0.88 | KDM4E (0.62) | KDM4ELMNAMAPTHTTHRH3 | |
| SCHEMBL20410843 | 0.85 | KDM4E (0.59) | KDM4ELMNAMAPTHTTHRH3 | |
| SCHEMBL30863841 | 0.82 | KDM4E (0.56) | KDM4ELMNAMAPTHTTHRH3 | |
| SCHEMBL1338857 | 0.82 | KDM4E (0.56) | KDM4ELMNAMAPTHTTHRH3 | |
| SCHEMBL1624547 | 0.81 | KDM4E (0.54) | KDM4ELMNAMAPTHTTHRH3 | |
| SCHEMBL8491691 | 0.81 | HPGD (0.55) | KDM4ELMNAMAPTHTTHRH3 | |
| SCHEMBL20410735 | 0.81 | KDM4E (0.54) | KDM4ELMNAMAPTHTTHRH3 | |
| SCHEMBL20410959 | 0.81 | KDM4E (0.58) | KDM4ELMNAMAPTHTTHRH3 | |
| SCHEMBL4748328 | 0.81 | KDM4E (0.54) | KDM4ELMNAMAPTHTTHRH3 | |
| SCHEMBL1621903 | 0.80 | KDM4E (0.50) | KDM4ELMNAMAPTHTTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| CN-101528690-A | Isoindoline derivatives for the treatment of arrhythmias | ASTRAZENECA AB (SE) | 2009-09-09 | — | — | CN | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-0427160-B1 | Benzylselenobenzamides of aminopyridines and picolylamines | NATTERMANN A & CIE (DE) | 1995-04-05 | — | — | EP | disclosed |
| EP-0427125-B1 | Benzylseleno-benzamides of anilines and benzylamines | NATTERMANN A & CIE (DE) | 1994-07-13 | — | — | EP | disclosed |
| EP-0510947-A1 | N-Hydroxy (thio)ureas as 5-lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 1992-10-28 | — | — | EP | disclosed |
| US-5141955-A | ANTI-INFLAMMATORY BENZYLSELENOBENZAMIDES MADE FROM ANILINES AND BENZYLAMINES | A. NATTERMANN & CIE. GMBH (DE) | 1992-08-25 | — | — | US | disclosed |
| US-5130485-A | For treatment of asthma, arthritis, allergy, inflammatory bowel disease, psoriasis, respiratory system disorders and antiischemic agents | ELI LILLY AND COMPANY (US) | 1992-07-14 | — | — | US | disclosed |
| US-5114954-A | ANTIINFLAMMATORY BENZYLSELENOBENZAMIDES FROM AMINOPYRIDINES AND PICOLYLAMINES | A. NATTERMANN & CIE. GMBH (DE) | 1992-05-19 | — | — | US | disclosed |
| EP-0427160-A1 | Benzylselenobenzamides of aminopyridines and picolylamines | A. Nattermann & Cie. GmbH (DE) | 1991-05-15 | — | — | EP | disclosed |
| EP-0427125-A1 | Benzylseleno-benzamides of anilines and benzylamines | A. Nattermann & Cie. GmbH (DE) | 1991-05-15 | — | — | EP | disclosed |
| US-4647565-A | 2-(2-quinazolinylaminoalkoxymethyl)-1,4-dihydropyridine derivatives as cardiovascular agents | PFIZER INC. (US) | 1987-03-03 | — | — | US | disclosed |
| EP-0168151-A1 | Dihydropyridine cardiovascular agents | Pfizer Limited (GB) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | KDM4E 4057/4885LMNA 228/4885MAPT 4504/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | KDM4E 4100/4885LMNA 461/4885MAPT 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.